Publication:
Dual bioresponsive antibiotic and quorum sensing inhibitor combination nanoparticles for treatment of Pseudomonas aeruginosa biofilms in vitro and ex vivo

dc.contributor.authorSingh, Nishant
dc.contributor.authorRomero, Manuel
dc.contributor.authorTravanut, Alessandra
dc.contributor.authorMonteiro, Patricia F
dc.contributor.authorJordana-Lluch, Elena
dc.contributor.authorHardie, Kim R
dc.contributor.authorWilliams, Paul
dc.contributor.authorAlexander, Morgan R
dc.contributor.authorAlexander, Cameron
dc.date.accessioned2024-09-10T13:10:32Z
dc.date.available2024-09-10T13:10:32Z
dc.date.issued2019-10-01
dc.description.abstractMany debilitating infections result from persistent microbial biofilms that do not respond to conventional antibiotic regimens. A potential method to treat such chronic infections is to combine agents which interfere with bacterial biofilm development together with an antibiotic in a single formulation. Here, we explore the use of a new bioresponsive polymer formulation derived from specifically modified alginate nanoparticles (NPs) in order to deliver ciprofloxacin (CIP) in combination with the quorum sensing inhibitor (QSI) 3-amino-7-chloro-2-nonylquinazolin-4(3H)-one (ACNQ) to mature Pseudomonas aeruginosa biofilms. The alginate NPs were engineered to incorporate a pH-responsive linker between the polysaccharide backbone and the QSI, and to encapsulate CIP via charge-charge interactions of the positively-charged drug with the carboxyl residues of the alginate matrix. In this way, a dual-action release of antibiotic and QSI was designed for the low-pH regions of a biofilm, involving cleavage of the QSI-linker to the alginate matrix and reduced charge-charge interactions between CIP and the polysaccharide as the alginate carboxyl side-chains protonated. When tested in a biofilm model the concomitant release of CIP + QSI from the pH-responsive nanoparticles significantly reduced the viability of the biofilm compared with CIP treatment alone. In addition, the alginate NPs were shown to penetrate deeply into P. aeruginosa biofilms, which we attribute in part to the charges of the NPs and the release of the QSI agent. Finally, we tested the formulation in both a 2D keratinocyte and a 3D ex vivo skin infection model. The dual-action bio-responsive QSI and CIP release nanoparticles effectively cleared the infection in the latter, suggesting considerable promise for combination therapeutics which prevent biofilm formation as well as effectively killing mature P. aeruginosa biofilms.en
dc.description.sponsorshipThis work was supported by the Engineering and Physical Sciences Research Council [grant numbers EP/N006615/1 and EP/K005138/1, EP/N03371X/1]; the Biotechnology and Biological Sciences Research Council (BBSRC) [grant number BB/R012415/1] and the Royal Society [Wolfson Research Merit Award WM150086] (to CA). This project has received funding from the EMPIR programme co-financed by the Participating States and from the European Union's Horizon 2020 research and innovation programme [grant reference 15HLT01 MetVBadBugs]es_ES
dc.format.number10es_ES
dc.format.page4099-4111es_ES
dc.format.volume7es_ES
dc.identifier.citationSingh Nishant, Romero M, Travanut A, Monteiro PF, Jordana-Lluch E, Hardie Kim R, et al. Dual bioresponsive antibiotic and quorum sensing inhibitor combination nanoparticles for treatment of Pseudomonas aeruginosa biofilms in vitro and ex vivo. Biomater Sci. 2019 Oct 01;7(10):4099-111.en
dc.identifier.doi10.1039/c9bm00773c
dc.identifier.e-issn2047-4849es_ES
dc.identifier.issn2047-4830
dc.identifier.journalBiomaterials Sciencees_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/14598
dc.identifier.pubmedID31355397es_ES
dc.identifier.puiL629427611
dc.identifier.scopus2-s2.0-85072628126
dc.identifier.urihttps://hdl.handle.net/20.500.12105/22804
dc.identifier.wos487753500010
dc.language.isoengen
dc.publisherRoyal Society of Chemistry (RSC)
dc.relation.publisherversionhttps://dx.doi.org/10.1039/c9bm00773cen
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution 3.0 Unported*
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/*
dc.subject.decsCiprofloxacina*
dc.subject.decsConcentración de Iones de Hidrógeno*
dc.subject.decsAnimales*
dc.subject.decsPercepción de Quorum*
dc.subject.decsPruebas de Sensibilidad Microbiana*
dc.subject.decsPorcinos*
dc.subject.decsHumanos*
dc.subject.decsNanopartículas*
dc.subject.decsInfecciones por Pseudomonas*
dc.subject.decsPseudomonas aeruginosa*
dc.subject.decsLínea Celular*
dc.subject.decsBiopelículas*
dc.subject.meshBiofilms*
dc.subject.meshNanoparticles*
dc.subject.meshMicrobial Sensitivity Tests*
dc.subject.meshAnimals*
dc.subject.meshQuorum Sensing*
dc.subject.meshHumans*
dc.subject.meshCell Line*
dc.subject.meshCiprofloxacin*
dc.subject.meshHydrogen-Ion Concentration*
dc.subject.meshPseudomonas aeruginosa*
dc.subject.meshSwine*
dc.subject.meshPseudomonas Infections*
dc.titleDual bioresponsive antibiotic and quorum sensing inhibitor combination nanoparticles for treatment of Pseudomonas aeruginosa biofilms in vitro and ex vivoen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublicationf873b730-a584-43b3-9018-d156aa9d413f
relation.isPublisherOfPublication.latestForDiscoveryf873b730-a584-43b3-9018-d156aa9d413f

Files